Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762457 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL8255549 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13724787 | 0.91 | CTSK (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24855543 | 0.86 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21284248 | 0.86 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2726957 | 0.86 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14302356 | 0.84 | CTSK (0.60) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23677838 | 0.84 | CTSK (0.60) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18925259 | 0.84 | CTSK (0.58) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL66302 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| WO-2018200625-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3364958-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | CTSK 4241/4885CTSS 3964/4885CA1 4323/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | CTSK 4783/4885CTSS 4782/4885CA1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.